Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy

Zeng, Lixia; Kanwar, Yashpal S.; Amro, Nail; Phillips, Carrie; Molitch, Mark E.; Batlle, Daniel; Danesh, Farhad R.

doi:10.1046/j.1523-1755.2003.00013.x

Cited by 8 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant DNA methylation has been implicated in many human diseases including DN (Zeng et al, 2003;Kato and Natarajan, 2014). To explore the reason for down-expression of let-7a in DN, DNA methylation in let-7a promoter region was focused on in this study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1

Peng

Liu

Peng

et al. 2015

Gene

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Despite the great progresses that have been made in recent decades, the mechanism involved in DN is not fully understood. Emerging evidence suggested that DNA methylation may be involved in the regulation of DN (Zeng et al, 2003;Kato and Natarajan, 2014). However, the exact mechanism remains unclear.…”

Section: Introductionmentioning

confidence: 96%

Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1

Peng

Liu

Peng

et al. 2015

Gene

View full text Add to dashboard Cite

“…A total of 320 candidate genes for diabetic nephropathy (DN) were initially selected for this study. This gene list comprised genes previously identified as differentially expressed in cell models of DN and renal biopsies (n = 210), [23][24][25][26] genes in which DNA polymorphisms have been reported to be positively associated with DN in type 1 or type 2 diabetes in at least two separate reports (n = 35), two genes previously investigated in DNA methylation studies in DN (P16) and end-stage renal disease (P66SHC), 27,28 and a subset of genes in Notch, Wnt and TGFβ developmental pathways that are implicated in DN (n = 73) (Suppl. Table 2).…”

Section: Conflict Of Interestmentioning

confidence: 99%

Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines

Brennan¹,

Ehrich²,

Brazil

et al. 2009

Epigenetics

View full text Add to dashboard Cite

Previous reports have shown that DNA methylation profiles within primary human malignant tissues are altered when these cells are transformed into cancer cell lines. However, it is unclear if similar differences in DNA methylation profiles exist between DNA derived from peripheral blood leukocytes (PBLs) and corresponding Epstein-Barr Virus transformed lymphoblastoid cell lines (LCLs). To assess the utility of LCLs as a resource for methylation studies we have compared DNA methylation profiles in promoter and 5' regions of 318 genes in PBL and LCL sample pairs from patients with type 1 diabetes with or without nephropathy. We identified a total of 27 (~8%) genes that revealed different DNA methylation profiles in PBL compared with LCL-derived DNA samples. In conclusion, although the profiles for most promoter regions were similar between PBL-LCL pairs, our results indicate that LCL-derived DNA may not be suitable for DNA methylation studies at least in diabetic nephropathy.

show abstract

“…The expression level of the cyclin-dependent kinase inhibitor p16INK4a is significantly decreased in cultured skin fibroblasts from type 1 diabetic patients with diabetic nephropathy, possibly explaining their hyperplastic growth phenotype [53].…”

Section: Gene Expression Studiesmentioning

confidence: 99%

Diabetic Nephropathy: An Inherited Disease or Just a Diabetic Complication?

Berger

Mönks

Wanner

et al. 2003

Kidney Blood Press Res

View full text Add to dashboard Cite

Type 2 diabetic nephropathy is the most common cause of end-stage renal disease in western Europe and the United States. Although patients with overt nephropathy generally experience greater cumulative glycemic exposure, the difference in glycemic control between patients developing nephropathy and to those who did not could not be demonstrated. This observation is consistent with the finding that factors other than glycemic control are involved in the development of nephropathy. Genetic factors which specifically increase the susceptibility to nephropathy in patients with diabetes have been proposed. A range of linkage, association, and gene expression studies have been performed for revealing the genetic background of diabetic nephropathy but were not yet successful in identifying mutations which could explain the development of diabetic nephropathy in the majority of diabetic patients. Because of relatively small case numbers of all studies being performed so far, conclusions from those studies are limited. With the development of better technologies for an affordable genomewide association study using thousands of markers, it might become possible to unravel the genetic susceptibility factors for diabetic nephropathy. Comparing the expression levels of thousands of genes in patients and controls may identify key players in the pathogenesis of diabetic nephropathy and targets for pharmacologic intervention in the future.

show abstract

Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy

Cited by 8 publications

References 40 publications

Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1

Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1

Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines

Diabetic Nephropathy: An Inherited Disease or Just a Diabetic Complication?

Contact Info

Product

Resources

About